Pharmascience v. Janssen
Federal Court File T-732-22
We represented Janssen.
This was an action for damages under section 8 of the Patented Medicines Notice of Compliance Regulations relating to abiraterone acetate. The action was discontinued shortly before trial (May 2025).
A number of significant interlocutory motions were decided in the course of these proceedings, including decisions related to settlement privilege, the scope of financial production and non-party discovery.
